BioSpace News Archive

Daewoong Pharmaceutical, a global pharmaceutical company located in Seoul, announced its marvelous financial results for 2023.

Kyowa Kirin Co., Ltd. (TSE: 4151) today announced the enrollment of the first patient in a Phase 2 clinical trial, multi-center, randomized, double-masked, parallel group study of tivozanib eye drops (KHK4951).

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted under Priority Review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease.

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 11:20 a.m. ET.

Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2023 financial results before market opening on Tuesday, February 13, 2024.

Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”), announced today it has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company focused on precision biologics, to explore antibody-drug conjugates (ADCs) using Nascent’s lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element.

In a groundbreaking development for brain tumor care in Poland, the Neurosurgery Centre at N. Copernicus Hospital in Gdansk is thrilled to announce the imminent installation of the ZAP-X® Gyroscopic Radiosurgery® platform.

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO) today announced that management will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held at the Cliff Lodge in Snowbird, UT from February 13th – 14th.

StimLabs® announces FDA 510(k) clearance of Corplex P, the pioneering human umbilical cord-derived medical device.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced data demonstrating treatment with UX111 (ABO-102) AAV gene therapy resulted in rapid and sustained decreased levels of heparan sulfate (HS) in cerebrospinal fluid (CSF) in patients with Sanfilippo syndrome type A (MPS IIIA).